FDA approves first blood test to detect gene mutation associated with non-small cell lung cancer - FDA Press Releases

The U.S. Food and Drug Administration today approved the cobas EGFR Mutation Test v2, a blood-based companion diagnostic for the cancer drug Tarceva (erlotinib). This is the first FDA-approved, blood-based genetic test that can detect epidermal growth factor receptor (EGFR) gene mutations in non-small cell lung cancer patients. Such mutations are present in approximately 10-20 percent of non-small cell lung cancers (NSCLC).

from Food and Drug Administration--Press Releases http://ift.tt/1Vx48Wd
via IFTTT